FDA Approved: FOLOTYN — Supplemental Application (Acrotech Biopharma Inc)

View source ↗

Summary

FDA approved a supplemental application for FOLOTYN (pralatrexate) from Acrotech Biopharma Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Folotyn (pralatrexate)

Snippet

SUPPL AP for FOLOTYN (PRALATREXATE)